中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
4期
28-30
,共3页
岑海燕%施文瑜%徐梦麒%黄红铭%王信峰
岑海燕%施文瑜%徐夢麒%黃紅銘%王信峰
잠해연%시문유%서몽기%황홍명%왕신봉
多发性骨髓瘤%β2微球蛋白%乳酸脱氢酶类%药物疗法
多髮性骨髓瘤%β2微毬蛋白%乳痠脫氫酶類%藥物療法
다발성골수류%β2미구단백%유산탈경매류%약물요법
Multiple myeloma%Beta2-microglobulin%Lactate dehydrogenases%Drug therapy
目的 探讨多发性骨髓瘤(MM)患者血清β2微球蛋白(β2-MG)和乳酸脱氢酶(LDH)检测的临床意义.方法 采用生化法检测63例MM患者(MM组)和20例健康体检者(对照组)血清β 2-MG和LDH水平.结果 MM组血清β2-MG和LDH水平明显高于对照组[(3.81±0.62) mg/L比(2.43 ±0.91) mg/L和(296.4±34.7) U/L比(145.5±17.8) U/L,P＜0.05],且随MM临床分期增加,血清β2-MG和LDH水平逐渐增高(P＜0.05).此外,采用VAD方案治疗有效患者(54例)化疗后血清β 2-MG和LDH水平明显低于化疗前[(2.51±1.36) mg/L比(3.57±0.82)mg/L和(159.1±35.2) U/L比(285.3±87.6) U/L,P＜ 0.05],而无效患者(9例)化疗前后血清β2-MG及LDH水平比较差异无统计学意义(P＞0.05).结论 血清β 2-MG和LDH水平可作为MM患者临床分期、化疗预后及疗效判断的辅助指标.
目的 探討多髮性骨髓瘤(MM)患者血清β2微毬蛋白(β2-MG)和乳痠脫氫酶(LDH)檢測的臨床意義.方法 採用生化法檢測63例MM患者(MM組)和20例健康體檢者(對照組)血清β 2-MG和LDH水平.結果 MM組血清β2-MG和LDH水平明顯高于對照組[(3.81±0.62) mg/L比(2.43 ±0.91) mg/L和(296.4±34.7) U/L比(145.5±17.8) U/L,P＜0.05],且隨MM臨床分期增加,血清β2-MG和LDH水平逐漸增高(P＜0.05).此外,採用VAD方案治療有效患者(54例)化療後血清β 2-MG和LDH水平明顯低于化療前[(2.51±1.36) mg/L比(3.57±0.82)mg/L和(159.1±35.2) U/L比(285.3±87.6) U/L,P＜ 0.05],而無效患者(9例)化療前後血清β2-MG及LDH水平比較差異無統計學意義(P＞0.05).結論 血清β 2-MG和LDH水平可作為MM患者臨床分期、化療預後及療效判斷的輔助指標.
목적 탐토다발성골수류(MM)환자혈청β2미구단백(β2-MG)화유산탈경매(LDH)검측적림상의의.방법 채용생화법검측63례MM환자(MM조)화20례건강체검자(대조조)혈청β 2-MG화LDH수평.결과 MM조혈청β2-MG화LDH수평명현고우대조조[(3.81±0.62) mg/L비(2.43 ±0.91) mg/L화(296.4±34.7) U/L비(145.5±17.8) U/L,P＜0.05],차수MM림상분기증가,혈청β2-MG화LDH수평축점증고(P＜0.05).차외,채용VAD방안치료유효환자(54례)화료후혈청β 2-MG화LDH수평명현저우화료전[(2.51±1.36) mg/L비(3.57±0.82)mg/L화(159.1±35.2) U/L비(285.3±87.6) U/L,P＜ 0.05],이무효환자(9례)화료전후혈청β2-MG급LDH수평비교차이무통계학의의(P＞0.05).결론 혈청β 2-MG화LDH수평가작위MM환자림상분기、화료예후급료효판단적보조지표.
Objective To evaluate the clinical significance of the serum β2-microglobulin (β 2-MG) and lactic dehydrogenase (LDH) in multiple myeloma (MM) patients.Methods The serum levels of β2-MG and LDH in 63 MM patients (MM group) and 20 healthy person (control group) were measured by biochemical assay.Results The serum levels of β 2-MG and LDH in MM group were higher than those in control group[(3.81 ± 0.62) mg/L vs.(2.43 ± 0.91) mg/L and (296.4 ± 34.7) U/L vs.(145.5 ±17.8) U/L,P ＜ 0.05].Furthermore,the serum levels of β 2-MG and LDH increased gradually with MM clinical staging (P ＜0.05).After VAD chemotherapy,the serum levels of β 2-MG and LDH in clinical response MM patients(54 cases) were significantly decreased [(2.51 ± 1.36) mg/L vs.(3.57 ± 0.82) mg/L and (159.1 ± 35.2) U/L vs.(285.3 ± 87.6) U/L,P ＜ 0.05],while those in no response patients (9 cases)were unchanged (P＞ 0.05).Conclusion The serum levels of β 2-MG and LDH can be taken as a clinical index to classify the clinical phase,prognosis and effectiveness of chemotherapy in MM patients.
